Pulmonary hypertension in patients with chronic myeloid leukemia

Dasatinib, a tyrosine kinase inhibitor (TKI), induces pulmonary hypertension (PH) in patients with chronic myeloid leukemia (CML). However, information on other TKIs is limited. We retrospectively analyzed PH prevalence by reviewing transthoracic echocardiography (TTE) findings in a population of Ko...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Ik-Chan, Yeon, Sang-Hoon, Lee, Myeong-Won, Ryu, Hyewon, Lee, Hyo-Jin, Yun, Hwan-Jung, Sun, Byung Joo, Park, Jae-Hyeong, Jeong, Jin-Ok, Jo, Deog-Yeon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
4800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376321/
https://www.ncbi.nlm.nih.gov/pubmed/34414970
http://dx.doi.org/10.1097/MD.0000000000026975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376321/
https://www.ncbi.nlm.nih.gov/pubmed/34414970
http://dx.doi.org/10.1097/MD.0000000000026975

Ejemplares similares